Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis
Microorganisms · 11.06.2026 · 14 (6) · 1306
DOI: 10.3390/microorganisms14061306 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 11.06.2026. Verfasst von Jinjin Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, University of Waterloo, the Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant.
Abstract (Originalsprache)
The global probiotic market is expanding rapidly, driven by growing demand for accessible strategies to support gut health, preventive care, and microbiome-based interventions. However, this commercial growth contrasts with the limited number of clinically validated, mechanism-driven products, highlighting a persistent gap between market expansion, scientific evidence, and therapeutic translation. Most current probiotics remain dominated by conventional genera, including Lactobacillus, Bifidobacterium, Bacillus, Saccharomyces, and Streptococcus, whereas live biotherapeutic products (LBPs) remain scarce. Synthetic biology is beginning to address this gap by transforming probiotics from empirically selected strains into programmable microbial platforms that sense disease-associated signals and produce defined therapeutic outputs. Escherichia coli Nissle 1917 (EcN) offers a valuable model chassis for engineered probiotics because of its long history of human use, safety record, genetic tractability, transient gut colonization, and scalable cultivation. As a rare Gram-negative probiotic, EcN naturally produces outer membrane vesicles that support host interaction, immunomodulation, and therapeutic cargo delivery. This review links probiotic market expansion with live biotherapeutic development and uses EcN to discuss emerging engineering strategies, therapeutic opportunities, and remaining translational barriers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical Engineering, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada.
ORCID-Profile: C Perry Chou, Yilan Liu
Förderung
- Natural Sciences and Engineering Research Council of Canada
- University of Waterloo
- the Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant
- University of Waterloo Velocity Up Start Grant
Zitieren
APA
Chen, J., Chou, C. P., & Liu, Y. (2026). Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis. Microorganisms, 14(6), 1306. https://doi.org/10.3390/microorganisms14061306
Vancouver
Chen J, Chou CP, Liu Y. Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis. Microorganisms. 2026;14(6):1306. doi:10.3390/microorganisms14061306
BibTeX
@article{Chen2026,
author = {Chen, Jinjin and Chou, C Perry and Liu, Yilan},
title = {Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {6},
pages = {1306},
doi = {10.3390/microorganisms14061306}
}
EUVIMED